Short answer
Aurinia Pharmaceuticals Inc. (AUPH) filed an 8-K current report with the SEC on August 19, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Settlement resolves Teva patent litigation over generic 7.9 mg voclosporin capsules in the United States.
Aurinia Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Settlement resolves Teva patent litigation over generic 7.9 mg voclosporin capsules in the United States
- Generic-entry timing and launch restrictions depend on settlement terms in Exhibit 99.1
- Agreement may protect U.S. Lupkynis commercialization, supporting Aurinia’s revenue outlook
- Settlement removes litigation uncertainty but could affect future competitive dynamics upon generic entry
Item EX-99.1 · Exhibit EX-99.1
- Teva patent settlement removes litigation uncertainty over generic 7.9 mg voclosporin capsules
- Teva acknowledged Aurinia patents valid, enforceable, and infringed by U.S. commercial sales
- Generic entry barred until December 7, 2036, absent defined earlier contingencies and FDA approval
- Remaining infringement actions continue against DifGen, Dr. Reddy’s, Galenicum, Hikma, Lotus, Sandoz, and Zydus
- Settlement supports extended U.S. exclusivity for LUPKYNIS, Aurinia’s lupus nephritis therapy
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aurinia Pharmaceuticals Inc. 8-K filings
Get the next AUPH 8-K as it lands
Follow AUPH for push alerts, or ask the research agent what this filing means.